Date:
Location:
Title | VACCINES: The Ultimate Quest in COVID-19 |
Description |
Researchers and physician-scientists from the Harvard Medical School-led Massachusetts Consortium on Pathogen Readiness (MassCPR) and thought leaders will discuss the state of COVID-19 vaccine development, latest efforts, clinical trials underway, and others expected to launch soon. |
|
Topics include:
|
Audience | Scientifically curious lay public; journalists |
Format | 60-minute program, followed by 30-minute audience Q&A |
Presenters
|
George Q. Daley
Dean of the Faculty of Medicine, Harvard University
Lindsey Baden
Associate Professor of Medicine, Harvard Medical School
Director of Clinical Research, Brigham and Women’s Hospital
Dan Barouch
Professor of Medicine, Harvard Medical School
Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
Nicole Frahm
Exploratory Biomarker Leader, Bill & Melinda Gates Medical Research Institute
Affiliate Associate Member, Fred Hutchinson Cancer Research Center
Bisola Ojikutu
Assistant Professor of Medicine and of Global Health and Social Medicine, Harvard Medical School
Infectious Disease Specialist, Brigham and Women’s Hospital/Massachusetts General Hospital
Arlene Sharpe
Chair, Department of Immunology, Harvard Medical School
Co-director, Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women’s Hospital
Bruce Walker
Professor of Medicine, Harvard Medical School
Director, Ragon Institute of MGH, MIT and Harvard
Director, Harvard University Center for AIDS Research
|
About MassCPR
|
MassCPR is a multi-institutional effort formed in early March to address both the immediate implications of the COVID-19 pandemic as well as the long-term need for enhanced preparedness for emerging pathogens. This effort involves scientists across 15 Boston-area universities, medical schools, research institutes and teaching hospitals from a variety of disciplines, including virology, immunology, microbiology, epidemiology, pathology, diagnostics and therapeutics development, computational biology, and clinical medicine. The formation of MassCPR was enabled by a research agreement between Harvard University and the China Evergrande Group, with support being shared equally between Massachusetts-based researchers and colleagues at the Guangzhou Institute of Respiratory Health in China.
This event is made possible by the Maxwell Finland Lectureship Fund |